Authors: Tetef, ML Synold, TW Chow, W Leong, L Margolin, K Morgan, R Raschko, J Shibata, S Somlo, G Yen, Y Groshen, S Johnson, K Lenz, HJ Gandara, D Doroshow, JH

Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576

Authors: Lau, D Leigh, B Gandara, D Edelman, M Morgan, R Israel, V Lara, P Wilder, R Ryu, J Doroshow, J

Citation: D. Lau et al., Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial, J CL ONCOL, 19(2), 2001, pp. 442-447

Authors: Rusch, VW Giroux, DJ Kraut, MJ Crowley, J Hazuka, M Johnson, D Goldbeg, M Detterbeck, F Shepherd, F Burkes, R Winton, T Deschamps, C Livingston, R Gandara, D

Citation: Vw. Rusch et al., Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (intergroup trial 0160), J THOR SURG, 121(3), 2001, pp. 472-483

Authors: Fossella, FV DeVore, R Kerr, RN Crawford, J Natale, RR Dunphy, F Kalman, L Miller, V Lee, JS Moore, M Gandara, D Karp, D Vokes, E Kris, M Kim, Y Gamza, F Hammershaimb, L

Citation: Fv. Fossella et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated withplatinum-containing chemotherapy regimens, J CL ONCOL, 18(12), 2000, pp. 2354-2362

Authors: Lau, D Ryu, J Gandara, D Morgan, R Doroshow, J Wilder, R Leigh, B

Citation: D. Lau et al., Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer, SEM RAD ONC, 9(2), 1999, pp. 117-120

Authors: Murray, N Livingston, RB Shepherd, FA James, K Zee, B Langleben, A Kraut, M Bearden, J Goodwin, JW Grafton, C Turrisi, A Walde, D Croft, H Osoba, D Ottaway, J Gandara, D

Citation: N. Murray et al., Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group, J CL ONCOL, 17(8), 1999, pp. 2300-2308